Member Info for chester18

Anyone who has been listening for the last two months knows that the PFS is the first real blueprint for the potential mine. It will answer many questions about how Newcrest see the Ore Body at this time, transport and related costings.

The next piece of information is the Indicated Resource Estimate which will be a subdued figure, general opinion approx 5 million ounces.

So the PFS will point the way forward but the December MRE will put a much larger number of ounces on the board.

I honestly think the usual sell off after news will be very mute this time around. To much coming down the news pipeline.

Chester.

Morning Genghis15

You are absolutely correct the in pointing out that the cash on hand will not last much more than 6 or 7 months, so Rene will need to raise more capital, meaning dilution again.

My enthusiasm to buy more shares at today's price is that I see the following possibly playing out in Q1 2022.

There is a slight possibility that Fosun Pharma could reach a milestone payment giving the cash runway a boost but I don't think any of the exosomes collaborations will not generate up front payments.

When we reach March 2022 and the RP data is released I'm expecting that data to be positive and with the larger 1M and 2M cell injections I would hope the increase in 'sight repair / letters seen' to be even better than the original outcomes.

If I am reading the future correct the SP should rise on that positive data and that will give Rene the perfect opportunity to raise new capital without huge dilution.

In a perfect world at £3.00 a share the company could raise £45M and only increase the total shares to 72M.

I still have every confidence that our stem cell technology will ultimately make a huge difference for people suffering with Retinitus Pigmentosa.

Chester.

The FDA will be looking for potential mechanical and electrical failure's plus normal safety issues when using an electrical device. They will also test for contamination from regular use. For me the most important element is traceability of each Parsortix Plate from a diagnosis point of view, ensuring any retrieved cells are carefully notated and recorded to the correct patient.
Lastly, and this was discussed on this board, that there is security that the Parsortix Plates are always genuine products and not forged inaccurate copy's.

That's the Device side.

The FDA will also want to ensure that the medical claims made by Angle match up to their own investigative findings.

A positive FDA Approval will mean that the Parsortix System can be fully implemented in a hospital setting so it has to be fool proof, reliable and medically sound.

The FDA shoulders all the responsibility of that decision.

Chester.

Thanks for that Edison Note.

I think the next 3 months will provide ample time to gather a few more shares especially at the current SP level.
If the data is anywhere near as good as the predicted the MCap of £54M will be seen as cheap as chips....

This share moves really quickly, unfortunately in both directions, but from this level the upside is now well worth the some extra investment.

Just my opinion based on where we are and the values of Mergers and Acquisitions in the Stem Cell arena.

Chester.

Taken from the SA Covidity Study Plan :

Study Type : Interventional (Clinical Trial)
Estimated Enrolment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Open label, uncontrolled study.
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A First Time in Human Phase 1 Open-Label Study of the Safety, Tolerability, and Immunogenicity of COVIDITY Vaccine Administered by Needle-free Intradermal Injection or Needle-free Intramuscular Injection in Healthy Adults (COVIDITY-001)

Estimated Study Start Date : September 2021 ( Actual 5th October )
Estimated Primary Completion Date : April 2022
Estimated Study Completion Date : June 2022

This extract from the Covidity Trial Plan shows it is 'Open Label' which allows significant outcomes to be announced early if the company deems it necessary. The Study is over 26 weeks so the Safety Data may not arrive until April 2022.

I was hoping that the Safety Data would be 4 to 6 weeks after first subject dosed but it needs to arrive after all 40 subjects have been dosed and a few weeks passed for the last subject to be assessed.

Chester.

As Usual buys showing as sells.

My buy has gone through at 119.8475p so all the trades in that price range are buys.
Just thought it worth a heads up.

Chester.

@ PhilBanks

Afternoon Phil

I have had a reply from Reneuron and it simply states the following :

"The current study is a single study with sites in the US,UK and EU.
Data is reported for the study as a whole and as noted in the announcement the plan is to present early efficacy data on the subjects in the expansion cohort in Q1 2022" Best regards Reneuron.

So even though the US arm of the study was given the ok to continue ( 8th July Preliminary Results ) the company cannot single out that data from the whole study, therefore we will have to wait for the UK and EU arms to report, which now means we will not see that data until Q1 2022.

I know its a pain but as long as the Phase 2a study produces continued or improved positive data it will have been well worth the wait.

Chester.

Hi Nomlungu

Macmillan is such an important source of support at a time when help and guidance is really needed.

I have supported them for many years with contributions two or three times a year. About two years ago I set up a monthly payment which I'm sure they appreciate the regular income in these difficult times.

All the best
Chester.

Hi izstar

I don't mind keeping tabs on another years predictions, I think I'll leave it until 1st November.
The next twelve months should see TRX hit some pivitol milestones, New Contracts, Turnover and hopefully Break Even.

Chester.

Total of 44 trades today, just shows how under the radar Scancell is at the moment.
It's not as if Covid 19 has gone away but the doom and gloom is so muted at the moment.

We also have conflicting messages, some saying that Covid will be treated no more than a bad cold mid next year ( Oxford ) and the alternative view, we will need to develop boosters against current and emerging strains ( BionTech ).

Once Covidity is established as a Dual Acting ( N & S Proteins ) potential Universal Vaccine it will be in demand and I'm hoping that CEPI is keeping a close eye on our progress in South Africa.

Chester.

Plus it's proving up AvidiMab and the Needle Free Injections.

That's a lot for the news media and the pharma industry to digest once it has passed this first hurdle.

This is what we've been waiting for and discussed in great detail so let's enjoy this new phase of our investment......

Inanaco's clock has finally had its first chime !!

Chester.

Come on, the RNS just says ' we're back in the game '.

It is great to know that Scancell's Immunobody science has at long last been given the chance to be proven inside a human body.

Positive Safety Data is paramount to our Universal Vaccine being taken seriously, we need to know that there are no serious side affects and that data could be available in 4/6 weeks.

Chester.

Not the market response we expected. It would seem that without main stream media attention our potential Universal Vaccine is of moderate interest.

The SP will probably rise gradually until either the media see a worthy story or we reach the Safety Data RNS, which will be highly significant.

My hope is that we also hear news from the MODI1 Trial before the end of October.

Chester.

Really glad to see that RNS, by the time SCIB1 has reach 1st Patient Dosed we will all be very relaxed about it. But right now this is fantastic news.

SCLPers start your engines and may the best DNA Dual Acting Universal Vaccine Win....... : )

Chester.

With Newcrest still fine tuning the PFS and the fact that we are still missing quite a lot of Core Data from the June Report, will this quarterly also be the catalyst for the MRE to be upgraded to Indicated ?

What is the most plausible path, is it 'Core Results' then 'Indicated MRE' then 'PFS', the right way to expect the announcement order ?

Chester.

Afternoon Jurado

As I already support Macmillan Cancer Care with a set monthly donation I choose to make my donation to Soft Touch Arts via Virgin Money, which did last night. Having read about the charity I am really pleased to be able to contribute to their cause.

Chester.

Morning Sandhopper

You have been a solid contributor to this TRX board for along time, going off memory only, I think even back before I started to post here and that was back when the SP was around 25p ish. ( I call it them good old days .. lol ).

I truly hope you do prove them all wrong and we are able to discuss TRX long into the future with you.

It would be great to see 4p or 5p a share again.

I wish you all my very best for today and the future

Chester.

Hi Jurado

please let me know the name of your nominated charity

Best regards

Chester.

This time last year we were all concerned about the Covid Pandemic and effects it may have on all of our lives.
This looking forward to 12 months hence was at the very least a distraction at that time. My hope was that TRX could continue to move forward in the face of those difficulties and although the SP begs to differ I do think that the company is in a much stronger position than a year ago.

Again thank you to all of you that said you would take part, the Winner with the exact share price of 0.62p is of course 'Jurado'.

JonnyRod. 0.20p
Nomlungu. 0.30p
Sinden888. 0.57p

Jurado. 0.62p ** THE WINNER **
THE CLOSING PRICE 01-10-2021 = >>0.62p >>

MRK2020. 0.70p
TheOldBee. 0.79p
ChrissyDude. 0.83p
Chester. 0.91p
Stuofthetoon . 0.95p
GinandMilk. 0.97p
KJM100K. 1.01p
Scoobyrex. 1.08p
DoneK. 1.1p
JoeSoap1. 1.19p
Andysmi. 1.20p
LunchBoxBill. 1.21p
theAccountant. 1.25p
Ohmni. 1.27p
HBomb5. 1.28p
Mark@1973. 1.30p
SC888. 1.31p
LivenLearn 1.38p
Messi10. 1.45p
Owennoone. 1.48p
theonlywayis.. 1.50p
Danielu11 1.51p
RN1MLT 1.56p
Shovel53. 1.57p
Smokey2. 1.68p
Jimjam. 1.70p
Sandhopper 1.75p
learn19 1.80p
Icecool. 1.99p
Krayl49 2.00
littlebricks 2.06p
Specialonek 2.50p
brittany 2.77p
ISATony 3.35p

My best wishes to all of you.

Maybe we should all hope that in twelve months from now ISATony is spot on.

Chester.

Hi grizzlyb

That just adds to the lack of clarity, I hope I do receive and comprehensive answer from the company.
If I do not hear back by early next week I'll ring them as I feel it is important that we have all the facts.

Chester.